An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
Paul JankThomas KarnMarion T van MackelenberghJudith LindnerDenise TreueJens HuoberKnut EngelsChristine SolbachKurt DieboldFrederic MarméVolkmar MuellerAndreas SchneeweißHans-Peter SinnTanja FehmChristian SchemElmar StickelerPeter Andreas FaschingJan BudcziesBärbel FelderValentina NekljudovaJohannes HoltschmidtMichael UntchCarsten DenkertSibylle LoiblPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
PIK3CA hotspot mutation p.H1047R are associated with worse pCR rates after NACT in HER2pos BC, while hotspot mutations in exon 9 seems to have less impact.